[Caution] not approved anywhere. keep posts descriptive.
co-agonism. That is the whole post, but I will justify it. Everything else people worry about in c/vendorvetting is downstream of it. Titration speed, muscle cramps, the endless dose arguments — most of it resolves if you sort co-agonism out first, and almost nobody does. I say this having got it wrong for 15 months.…
Disagree. What you are describing is consistent with CagriSema, not with what you concluded.
long-acting amylin is co-agonism, different satiety profile
not approved anywhere, keep posts descriptive, not instructional
amylin receptor distribution is different from GLP-1
the amylin agonist pool is small, community is satiety